Only 63% of INNs from the list of vital and essential drugs are produced in Russia in a full cycle

There are 6.8 thousand trade names (TN) registered in Russia for active substances included in the VED list. Only 30% (2,016 TN) of them are produced from Russian substances, 40% - from imported API. Foreign drugs in the total number of TN from the VED list make up a share of 23%. Only 3% of TN are supplied to Russia from the EAEU member countries.

Analysts emphasized that out of 2,016 TN classified as full-cycle production, information on only 1,020 drugs can be considered reliable, since their registration certificates indicate one or more domestic substances. The documents for the remaining 996 TN also contain imported APIs, which does not allow a conclusion to be made about where the substances actually used in production are manufactured.

Cursor named systemic antimicrobial agents (the group includes vaccines) as the ATX group with the largest number of drugs that are fully localized in Russia – the share of fully domestic products in it was 77%. The analysts named antiparasitic drugs, insecticides and repellents as the least deeply localized group of drugs – only 25% of INNs from this ATX group have full-cycle production in the Russian Federation.

According to Curcor, the largest volumes of import of finished drugs from the list of vital and essential drugs are formed by countries recognized by the Russian Federation as unfriendly - registration certificates for 923 TN belong to companies from these countries. This list includes, in particular, the countries of the European Union, the USA, Canada and Japan.

In early July 2025, the Ministry of Industry and Trade presented a draft of the Rules for the voluntary submission of data on confirmation of the country of origin of products to the state system for monitoring the circulation of goods subject to labeling. The agency plans to fully launch the traceability system, which has been undergoing testing since the end of 2023, from September 1, 2025. Using the platform, regulators will establish the actual country of origin of drugs for the further provision of benefits to manufacturers from the EAEU under the national regime.